Second, patient heterogeneity—arising from diverse genetic, epigenetic, and immunological profiles—limits the predictive accuracy of current biomarkers such as PD-L1 expression and tumor mutational burden (117, 118). The gene discussed is CD274; the disease is neoplasm.